News

« Back

ESA Guidance

Please find attached a Direct Healthcare Professional Communication which has been sent out regarding Recombinant human erythropoietins: Risk of severe cutaneous adverse reactions.

ESA Guidance ESA Guidance
16-11-2017

« Back